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ABSTRACT 
OQectives: To determine the prevalence of human immuno- 
deficiency virus-i and -2 infection in voluntary blood donors at 
a university hospital in the third largest city of Turkey and to eval- 
uate the HIV testing strategy for notifying blood donors. 
Methods: Between July 1995 and August 1997, 36,373 vol- 
untary blood donors who met the criteria for donating blood 
were tested for the presence of HIV-I and -2 antibodies by 
using an automated enzyme-linked fluorescent immunoassay. 
Repeatedly reactive samples were subjected to a different 
enzyme-linked immunosorbent assay (ELISA) and a line 
immunoassay (LIA) for the detection of antibodies. 
Results: Of the 36,373 samples tested 72 were found to be 
repeatedly reactive or borderline by the first screening enzyme 
immunoassay (EIA). None of the 72 samples was reactive by 
the second EIA. These samples were further tested by LIA: 64 
were negative on the line immunoassay and 8 were indeter- 
minate. Three of eight donors who had indeterminate results 
by LIA were tested for HIV-1 DNA by polymerase chain reac- 
tion (PCR) and were found to be negative. One additional donor 
with an indeterminate LIA was found to be negative by EIA 
and LIA during the 6-month follow-up period. 
Conclusion: Donor questioning, repeat EIA testing, LIA testing, 
and HIV-l DNA analysis did not confirm evidence for HIV infec- 
tion among this blood donor population. Blood donor notifica- 
tion of test results according to the World Health Organization 
(WHO) strategy Ill was found to be an appropriate approach. 
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Following the emergence of human immunodeficiency 
virus (HIV) infection as a transfusion-transmitted disease, 
the safety of blood has been a great concern. From 1985, 
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when the first case of acquired immunodeficiency syn- 
drome (AIDS) was reported, through December 1997, 
731 cases of HIV infection have been documented in 
Turkey, according to the Ministry of Health. Legally, only 
voluntary blood donation has been permitted and donors 
have been screened for antibody to HIV since 1987. 
The objective of this study was to determine the 
prevalence of HIV-l and -2 infection and to evaluate the 
HIV testing strategy in voluntary blood donors at a uni- 
versity teaching hospital in Izmir, Turkey. 
PATIENTS AND METHODS 
Study Population 
This study was carried out at the blood bank of Ege Uni- 
versity Medical Center, a 1800-bed hospital serving a pop- 
ulation of 3 million people. All voluntary and replacement 
blood donors seen at the hospital blood bank between 
July 1995 and August 1997, received written information 
about the risks of transmitting disease through blood and 
were asked to fill out a questionnaire to determine if they 
met the criteria for donating blood. Blood testing was 
then performed. 
Assays Performed 
Samples were tested for HIV-l and -2 antibodies, hepati- 
tis B surface antigen (HBsAg), hepatitis C virus (HCV) 
antibodies, and syphilis. Screening for HIV-l and -2 anti- 
bodies was done by an automated enzyme-linked fluo- 
rescent immunoassay (Vidas HIV-l and -2, BioMerieux, 
France). Samples with positive or borderline results were 
not accepted for donation and were retested by the same 
enzyme immunoassay (ELA) after centrifugation. Repeat- 
edly reactive or borderline samples were retested by an 
EL4 from another manufacturer (Vironostica HIV Uniform 
II, Organon Teknika, Nederland) and a line immunoassay 
(LIA, LiaTek HIV III, Organon Teknika, Nederland). 
Donors who had positive bands in LIA were coun- 
selled and asked to give an appropriate blood sample for 
HIV-l proviral DNA polymerase chain reaction (PCR). 
Amplicor HIV-l PCR (Hoffman-La Roche, Switzerland) 
was used for PCR analysis according to the manufacturer’s 
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instructions. They also were advised to come for a sec- 
ond visit in 3 months for re-evaluation. 
An automated EL4 was used for HBsAg and anti-HCV 
tests. Rapid plasma reagin (RPR) test was used for syphilis 
screening. 
RESULTS 
During the study period, 36,373 samples were screened 
(Table 1). Among these, 72 (0.19%) were repeatedly reac- 
tive or borderline on the first assay: 26 of 72 were repeat- 
edly borderline; 2 of 72 were borderline on the first run 
and reactive on the second run; 4 of 72 were reactive on 
the first run and borderline on the second run, and 40 of 
72 were repeatedly reactive. In the study, the highest pos- 
itive test value was found to be 4.35 (test threshold value 
was 2 0.57, according to the manufacturer). None of these 
72 samples was found to be reactive when retested by 
the second EL4 system (Organon Teknika). These sam- 
ples were subjected to further testing by line immuno- 
assay. Among these, 64 were negative and 8 were inter- 
preted as indeterminate, having a single reactive band. 
In seven of eight samples, the band present was p24 pro- 
tein. In the remaining one, gp41 was the reactive band. 
All the blood donors with indeterminate LIA results 
denied any high-risk behavior. For three of them, HIV-l 
DNA PCR was performed and was found to be negative 
in all three. Two of these three cases continued to have 
negative EL4 and PCR test results 3 months after the ini- 
tal testing. One case repeatedly had a p24 reactive band 
during 1 year of follow-up. One additional donor of the 
eight cases with indeterminate LIA results, was found to 
be negative for HIV-l and -2 antibodies by EIA and LZA 
during the 6-month follow-up period; PCR tlesting was 
not done in this case. The remaining four donors did not 
agree to take part in the follow-up testing. 
DISCUSSION 
Screening blood donors for antibody to HIV has been 
mandatory in Turkey since 1987. Licensed sex workers 
and males living abroad and applying for military service 
in Turkey are the other groups that require HIV testing. 
During pregnancy, HIV testing is frequently done even 
though it is not mandatory The results that are positive 
by both HIV-l and -2 EL4 and confirmation tests must be 
reported to the Ministry of Health. Between 1985 and 
December 1997, 731 HIV-positive cases have been 
reported throughout the country. The route of infection 
was found to be heterosexual transmission in 285 (42%) 
of the cases. 
In 1996, three transfusion-related HIV cases were 
reported in Turkey, In two of these cases, the index blood 
donor was the same, and he was in the “window period” 
Table 1. Results of Screening Tests on 
36,373 Blood Samples from Prospective Donors 
Screening Test 
Anti-HIV-l and -2 
First EIA 
Second EIA 
Line immunoassay 
HIV-I proviral DNA PCR 
Other tests 
HBsAg 
Anti-HCV 
RPR 
Number Positive 
72 (0.19%) repeatedly 
reactive or borderline 
O/72 positive 
O/72 positive; 8/72 indeterminate 
O/3 positive 
1068 (2.93%) 
237 (0.65%) 
0 
when he had donated blood. In the other case, blood was 
transfused before the serology results were available. 
In this study, 36,373 blood samples were tested dur- 
ing a 25-month period, and none was found to be posi- 
tive. In the same hospital, between 1995 and 1997, none 
of the 1412 pregnant women screened for HIV-l and -2 
was found to be positive (Unpublished data). 
In another study in Istanbul during a lo-year period 
(1987-1996), 966,075 blood donors were screened for 
HIV-l and -2 antibodies. In that study, the lowest rate of 
HIV seropositivity according to strategy II recommenda- 
tions by the World Health Organization (WHO) was 
0.0001% in 1989, and the highest was 0.007% in 1993.‘~’ 
In another study reported from Isparta, a city in central 
Turkey, 38,065 blood donors were tested, and the rate of 
seropositivity confirmed by Western blot was 0.0052%.3 
The low prevalence of HIV-l and -2 antibodies in the 
aforementioned studies found among blood donors and 
women attending prenatal clinics indicated that HIV 
infection is not yet widely disseminated in the general 
population. In this study, blood samples also were tested 
for hepatitis B virus (HBV), an infection that has similar 
transmission routes as those for HIV It was found that 
IO68 (2.9%) of the prospective donors were positive for 
HBsAg. This finding indicates that HBV is still the leading 
parenterally or sexually transmitted infectious agent in 
the donor population in Turkey. 
The WHO strategy III for donor notification recom- 
mends that three consecutive tests should be required 
in areas where the prevalence of HIV infection is below 
1O%.2 According to the WHO recommendations, samples 
negative on the first assay or positive on the first but neg- 
ative on the second assay should be considered negative. 
Even though none of the donors in the present study 
required a third testing, because all the second EL4 results 
were negative according to these criteria, the authors 
performed further testing with LIA to evaluate the rec- 
ommended strategy. Eight of the 72 (11.1%) were inter- 
preted as indeterminant by LIA. The reactive band was 
p24 in seven of eight samples and was gp41 in the 
remaining one. Presence of a p24 band may be asso- 
ciated with the early stages of HIV seroconversion. 
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However, it has been shown that an indeterminate West- 
ern blot result in a low-risk population (e.g., blood 
donors) is not usually associated with seroconversion.4-6 
Line immunoassay is preferred to Western blot for con- 
firmation, because studies report that it has a lower rate 
of indeterminate results.‘” 
In the present study, although all the donors with 
indeterminate LIA results denied any high-risk behavior, 
they were advised to provide another blood sample for 
PCR testing. Four subjects consented to the follow-up; 
retesting was by PCR or EIA, 3 months after the initial 
testing, and all four were found to be negative. Four donors 
refused further testing. The lack of follow-up on four of 
eight patients with an indeterminate LIA makes it impos- 
sible to draw a definitive conclusion on the value of LL4 
in this population. The lack of any positive result on 72 
samples, the high frequency of indeterminate results, and 
the high cost of the test limits the attractiveness of LIA for 
routine use. Finally, notification of donors of their test 
results according to the WHO strategy III was found to be 
appropriate in this blood donor population. 
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